15 March 2023 | News
QDENGA is the only dengue vaccine approved in Brazil for use in individuals without need for pre-vaccination testing
Image credit: shutterstock
Japanese pharmaceutical company Takeda's dengue vaccine, QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), has been approved in Brazil by the National Health Surveillance Agency (ANVISA) for the prevention of dengue caused by any of the four virus serotypes that can be found in individuals from 4 to 60 years of age.
The use of QDENGA should be in accordance with official recommendations of the regulatory agency.
Dengue is a mosquito-borne viral disease that poses a significant global public health threat to half the world’s population, with risk of infection in over 125 countries including many in Latin America. Severe dengue has become a leading cause of hospitalisation and death among children and adults in some of the countries within the region.
In 2022, Brazil saw more than 1.4 million cases of dengue and more than 1,000 deaths according to the Ministry of Health, a 162.5% increase in cases compared to 2021.
The approval of QDENGA is based on results across 19 Phase 1, 2 and 3 trials with more than 28,000 children and adults, including four and a half years of follow-up data from the global, pivotal Phase 3 Tetravalent Immunisation against Dengue Efficacy Study (TIDES) trial.